RNS Number:2501Y Syntopix Group plc 13 June 2007 For immediate release 13 June 2007 SYNTOPIX GROUP PLC ('Syntopix' or 'the Company') FIRST PARTICIPANTS DOSED IN ACNE TRIAL Syntopix Group plc (AIM: SYN), the drug discovery and development company focused on dermatological diseases, is pleased to announce that the first participants have been treated in the Company's Phase I trial of three new topical preparations for acne. The double-blind, randomised controlled trial, using 24 healthy volunteers, will seek to demonstrate the antibacterial efficacy of the formulated compounds and therefore evaluate their potential to compete with antibiotics and benzoyl peroxide in the acne market. The Syntopix compounds in this trial include SYN 0017 (an antioxidant present in foods and cosmetics), SYN 0401 (an antifungal present in personal healthcare products), and a combination of SYN 0017 and SYN 0016 (an oxidising agent present in pharmaceutical preparations). All three of these compounds have a history of safe use in man in line with the Company's strategy of seeking to reduce the risks and timelines associated with drug discovery by focussing on compounds with known properties. It is anticipated that the trial will be completed within three months and that the results of the trial will be available later this year. Stephen Jones, Syntopix' CEO, commented: 'We are delighted that the first compounds from our novel screening and development programme are now being assessed in the clinic. This is a significant milestone for the Company, and an important step in identifying compounds that can be developed as medicines for the treatment of acne.' ENDS For further information please contact: Syntopix Group plc 0845 125 9204 Stephen Jones, Chief Executive Officer Rod Adams, Chairman KBC Peel Hunt Ltd 020 7418 8900 Capel Irwin Buchanan Communications 020 7466 5000 Mark Court/Catherine Breen Notes to editors About Syntopix Group plc Syntopix, a group focused on the discovery and development of drugs for the topical treatment of dermatological diseases. The company was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading experts in skin microbiology, with initial funding from The Wellcome Trust. Syntopix' strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds. The company concentrates on compounds and combinations of compounds that have a history of safe use in man; and that have well characterised properties, for example antimicrobials and anti-inflammatories. The Group currently has 10 pending UK patent applications. Syntopix is currently concentrating on acne and Staphylococcus aureus infections and has identified a pipeline of lead drug candidates that it intends to take through pre-clinical and, as appropriate, clinical trials. The Group intends to out-license products to commercial partners on obtaining proof of principle and to seek co-development partnerships. The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds. Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose Technology Limited and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For further information please visit www.syntopix.com. This information is provided by RNS The company news service from the London Stock Exchange END MSCSFLFWESWSEDM
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Synnovia PLC's (LON:SYN) chairman Faisal Rahmatallah tells Proactive London's Andrew Scott they saw record sales growth in the year to March 2019.
He adds that adjusted profits were just above flat as the plastic components and film packaging specialist invested for growth.